Intercept Pharmaceuticals (NASDAQ:ICPT)‘s stock had its “buy” rating restated by stock analysts at B. Riley in a report released on Monday, TipRanks reports. They presently have a $97.00 price objective on the biopharmaceutical company’s stock. B. Riley’s target price would suggest a potential upside of 102.46% from the company’s current price.

A number of other equities research analysts have also recently weighed in on ICPT. Goldman Sachs Group cut Intercept Pharmaceuticals from a “buy” rating to a “neutral” rating and reduced their price objective for the company from $150.00 to $60.00 in a research note on Monday. Wells Fargo & Co cut Intercept Pharmaceuticals from an “overweight” rating to an “equal weight” rating and reduced their price objective for the company from $146.00 to $46.00 in a research note on Monday. Needham & Company LLC reiterated a “buy” rating and issued a $150.00 price objective on shares of Intercept Pharmaceuticals in a research note on Monday, May 11th. Chardan Capital reiterated a “buy” rating and issued a $145.00 price objective on shares of Intercept Pharmaceuticals in a research note on Tuesday, May 12th. Finally, Credit Suisse Group cut Intercept Pharmaceuticals from an “outperform” rating to a “neutral” rating and reduced their price objective for the company from $137.00 to $59.00 in a research note on Monday. Eighteen investment analysts have rated the stock with a hold rating and seven have given a buy rating to the company. The stock currently has an average rating of “Hold” and a consensus target price of $81.48.

Shares of ICPT opened at $47.91 on Monday. The stock has a 50 day moving average price of $78.84 and a 200 day moving average price of $88.09. The company has a quick ratio of 4.19, a current ratio of 4.19 and a debt-to-equity ratio of 10.32. The company has a market capitalization of $2.55 billion, a price-to-earnings ratio of -4.47 and a beta of 1.82. Intercept Pharmaceuticals has a 52-week low of $44.50 and a 52-week high of $125.00.

Intercept Pharmaceuticals (NASDAQ:ICPT) last issued its quarterly earnings data on Monday, May 11th. The biopharmaceutical company reported ($2.86) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($2.94) by $0.08. Intercept Pharmaceuticals had a negative return on equity of 430.51% and a negative net margin of 127.53%. The company had revenue of $72.60 million during the quarter, compared to analysts’ expectations of $69.67 million. During the same quarter in the previous year, the business earned ($3.03) earnings per share. The firm’s revenue for the quarter was up 39.1% on a year-over-year basis. On average, equities analysts anticipate that Intercept Pharmaceuticals will post -11.3 EPS for the current fiscal year.

In related news, Director Paolo Fundaro sold 595,578 shares of the company’s stock in a transaction on Wednesday, May 13th. The stock was sold at an average price of $84.60, for a total transaction of $50,385,898.80. Following the transaction, the director now owns 19,433 shares of the company’s stock, valued at $1,644,031.80. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders have sold 595,817 shares of company stock worth $50,405,516 in the last ninety days. 23.70% of the stock is currently owned by corporate insiders.

Hedge funds have recently made changes to their positions in the stock. Prudential Financial Inc. acquired a new position in Intercept Pharmaceuticals during the fourth quarter worth $1,048,000. Squarepoint Ops LLC acquired a new stake in Intercept Pharmaceuticals in the first quarter valued at $766,000. AlphaCrest Capital Management LLC grew its holdings in Intercept Pharmaceuticals by 7.8% in the first quarter. AlphaCrest Capital Management LLC now owns 5,434 shares of the biopharmaceutical company’s stock valued at $342,000 after purchasing an additional 393 shares during the last quarter. CIBC World Markets Inc. acquired a new stake in Intercept Pharmaceuticals in the fourth quarter valued at $223,000. Finally, Dynamic Technology Lab Private Ltd acquired a new stake in Intercept Pharmaceuticals in the first quarter valued at $310,000. 76.46% of the stock is currently owned by hedge funds and other institutional investors.

About Intercept Pharmaceuticals

Intercept Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases. It markets Ocaliva, an farnesoid X receptor agonist approved in the United States, the European Union, and other jurisdictions for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid in adults.

Recommended Story: What is net income?

Analyst Recommendations for Intercept Pharmaceuticals (NASDAQ:ICPT)

Receive News & Ratings for Intercept Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intercept Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.